Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Lung Cancer
Interventions
DRUG

Imetelstat Sodium (GRN163L)

"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."

Trial Locations (4)

21201

University of Maryland Greenebaum Cancer Center, Baltimore

53792

University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison

75390

The University of Texas Southwestern Medical Center, Dallas

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Geron Corporation

INDUSTRY